Nucleic acid thermodynamics

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
화요일, 4월 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Retrieved on: 
월요일, 4월 22, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Nucleic acid thermodynamics, NTRA, Investment, Publication, Colorectal cancer, Genetic testing, SMART, DNA, NIPT, Patient, Kidney transplantation, NEJM, Clinical trial, ProActive, Chronic kidney disease, Cohort (statistics), Pharmaceutical industry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
  • Landmark cutting-edge science and clinical trial data based on Natera’s suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of Medicine (NEJM).
  • “When it comes to transforming patient care, high-quality science and data drive everything,” said Alexey Aleshin, M.D., chief medical officer & general manager of oncology at Natera.
  • We remain committed to generating evidence that supports the real-world impact of our innovations.”

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Retrieved on: 
목요일, 4월 11, 2024
Health, Surgery, Genetics, Clinical Trials, Research, Science, Biotechnology, Nucleic acid thermodynamics, University, NTRA, Risk, MD, Transplant, EGFR, DNA, Oportunidades, Patient, Microbiology, Biopsy, Maryland School, ProActive, Dentistry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection.
  • The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled at 54 participating transplant centers.
  • These data further support the Prospera Kidney test’s value as an early indicator of rejection vs biopsy.
  • Natera remains excited to continue pursuing additional clinical evidence and optimizing the management of kidney transplant patients for improved long-term outcomes.”

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

Retrieved on: 
화요일, 4월 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Nucleic acid thermodynamics, Trial of the century, Plasma, DdPCR, Digital, DNA, Patient, AACR, EGFR, NSCLC, AstraZeneca, Liquid biopsy, Medical imaging

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
  • These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical setting.
  • Biodesix supported this research by providing the EGFRm testing using Droplet Digital™ PCR* (ddPCR™) on plasma samples collected prior to treatment and three and six weeks after treatment initiation.
  • EGFRm testing is offered in a clinical setting by Biodesix as part of the GeneStrat® ddPCR targeted mutation test.

Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer

Retrieved on: 
금요일, 4월 5, 2024
Lung cancer, Liquid biopsy, Nucleic acid thermodynamics, Patient, NGS, Deletion, Blood, DNA, Urine, BDD, NSCLC, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced a collaboration with Apollomics, Inc.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced a collaboration with Apollomics, Inc.
  • This collaboration aims to advance the development of PredicineCARE™, a blood cell-free DNA (cfDNA) next-generation sequencing (NGS) assay, to identify non-small cell lung cancer (NSCLC) patients who may benefit from targeted therapy.
  • PredicineCARE™ was granted Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration on August 23, 2022.
  • PredicineCARE™ is a comprehensive, state-of-the-art NGS assay that interrogates point mutations/indels, fusions, amplifications, and deletions in key cancer-associated genes using cfDNA from liquid biopsy samples such as blood and urine.

Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing

Retrieved on: 
금요일, 4월 5, 2024
CDX, Nucleic acid thermodynamics, Tissue, NGS, DNA, RUO, Laboratory, Urine, BDD, Cancer, Liquid biopsy, Deletion, Blood, FDA, Food

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.
  • This offering presents a research-use-only (RUO) next-generation sequencing (NGS) kit packaged for genomic profiling across various cancers, facilitating global applications in clinical trials, companion diagnostics (CDx) development, and patient testing.
  • This newly introduced PredicineCARE™ NGS kit integrates a comprehensive, state-of-the-art NGS assay capable of detecting point mutations, indels, fusions, amplifications, and deletions in key cancer-associated genes.
  • “Predicine’s centralized global lab network coupled with the decentralized kitted offering provides a standardized approach to support clinical trials, CDx development and patient testing on a global scale.”

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
월요일, 4월 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

GRAIL Presents New Data on Galleri® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting

Retrieved on: 
수요일, 3월 27, 2024
Biotechnology, Other Health, Health, General Health, Oncology, Health Technology, Medical Devices, Research, Genetics, Science, Clinical Trials, Prostate cancer, Survival, Nucleic acid thermodynamics, Methylation, Cancer, MD, Medicine, AACR, Gene expression, Molecular biology, Medical imaging

“The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.

Key Points: 
  • “The data we are presenting at AACR continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection,” said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL.
  • Exhibiting 4-year overall survival follow-up demonstrating the prognostic significance of detecting cancer with a methylation-based cfDNA platform like Galleri.
  • Illustrating data demonstrating the power of Galleri to preferentially detect high grade, clinically significant prostate cancer over indolent cases.
  • In the precision oncology setting, GRAIL will discuss the adaptability of its Methylation Platform in identifying cancer histological and molecular subtypes through blood samples.

New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors

Retrieved on: 
화요일, 3월 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Plasma, Novartis, Nucleic acid thermodynamics, Patient, Biomarker, DNA, Cancer, Virtuoso, Oslo University Hospital, Rikshospitalet, Lutetium (177Lu) oxodotreotide, Medicine, Biobank, Somatostatin, FDA, Medical imaging

Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.

Key Points: 
  • Differences in plasma-derived cell free DNA (cfDNA) 5hmC profiles after administration of Lutathera revealed biological responses consistent with radioligand therapy mechanism of action hypothesis.
  • “Our research collaboration with Novartis has demonstrated the power of ClearNote Health’s cutting-edge epigenomic technology in the interrogation of predictive biomarkers of radioligand therapy response from a single blood draw,” said Dave Mullarkey, CEO of ClearNote Health.
  • The comparison of plasma-derived cfDNA 5hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and on treatment.
  • This collaboration underscores ClearNote Health's commitment to empowering biopharmaceutical innovation in developing better drugs through cutting-edge molecular diagnostic technologies.

Adela to Present Data from Tissue-Agnostic MRD Assay at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
화요일, 3월 19, 2024
Princess Margaret Cancer Centre, Detection, Interception, Nucleic acid thermodynamics, AACR, MRD, Sinai Health System, Biology, University Health Network

FOSTER CITY, Calif., March 19, 2024 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced data will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024 from its tissue-agnostic minimal residual disease (MRD) assay. These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment. Data will also be presented on the analytical performance of Adela's platform.

Key Points: 
  • These data demonstrate the feasibility of the assay for cfDNA cancer signal quantification and prognostic prediction in HPV-positive and HPV-negative head & neck cancers following treatment.
  • Dr. De Carvalho will also present in the session "New Liquid Biopsy Technologies for Detection and Characterization of Cancer".
  • Adela plans to commercialize its first product, a tissue agnostic test for minimal residual disease (MRD) monitoring, in 2025.
  • It can be applied across the entire cancer care continuum and is initially being developed for MRD and multi-cancer early detection.